DOI 10.36074/logos-18.08.2023.27

# REVOLUTIONIZING NEW DRUG RESEARCH: THE ROLE OF AI AND MACHINE LEARNING IN THE DISCOVERY OF NEW ANTIBIOTICS

**ORCID ID: 0009-0009-6661-2353** **Chrobak Daria**
MSc in Medical Biotechnology
Institute of Environmental Engineering and Biotechnology,
Faculty of Natural and Technical Sciences
*Opole University*

*POLAND*

***Abstract.*** *Recent technological advances have revolutionized drug discovery. Artificial intelligence (AI) and machine learning (ML) are among the most important new tools being used to identify novel drug targets. This study examines the role of AI and ML in the discovery of new antibiotics, such as abaucin, a process that involves the identification and study of small molecules that could be used as drugs to treat a variety of diseases. It discusses how AI and ML are used to analyze large datasets, identify previously unknown abaucin targets, and study the molecular interactions of known abaucins. It also examines the challenges associated with using AI and ML for drug discovery, such as the need for large datasets and complexity of molecular interactions. Finally, this paper provides an outlook on the potential of AI and ML to revolutionize drug research in the future.*

## Introduction

The pharmaceutical industry has long been grappling with the challenges of discovering new drugs to combat various diseases and improve human health. Historically, the process of drug discovery has been time-consuming, expensive, and often fraught with uncertain outcomes. However, the advent of Artificial Intelligence (AI) and Machine Learning (ML) has ushered in a new era of drug research, promising more efficient and targeted drug development processes. One prime example of AI's transformative potential in drug discovery is the recent success in the discovery of Abaucin, a groundbreaking medication with potential implications for a range of ailments.

### 1. AI and Machine Learning in Drug Discovery

AI and ML algorithms have emerged as game-changers in drug discovery due to their ability to analyze vast datasets and identify patterns that are beyond human comprehension. Traditional drug discovery often involves the testing of millions of chemical compounds, a process that is both labor-intensive and time-consuming. However, AI and ML can significantly accelerate this process by sifting through extensive databases to predict potential drug candidates, thereby narrowing down the pool for further experimental evaluation [3, 9].

These technologies leverage predictive models, pattern recognition, and advanced analytics to identify molecules that are most likely to interact with specific drug targets. By simulating molecular interactions, AI-driven drug discovery greatly enhances the efficiency of lead identification and optimization stages, leading to quicker and more targeted development processes [9, 10].

By harnessing the power of AI and machine learning, AI-driven drug discovery can significantly reduce the time and cost associated with traditional methods,

providing a more efficient approach to identify new antibiotic candidates and combat antibiotic resistance.

**2. Abaucin Discovery: A Triumph of AI and ML**

The discovery of Abaucin serves as a prime illustration of AI and ML's potential in drug research. Abaucin is a novel drug compound that exhibits strong inhibitory effects against a key enzyme associated with chronic inflammation and autoimmune diseases. The development of Abaucin is a significant milestone in the treatment of conditions like rheumatoid arthritis, inflammatory bowel diseases, and psoriasis [5, 10].

The process of Abaucin discovery relied heavily on AI and ML technologies. Researchers employed computational models to screen and analyze massive molecular databases to identify compounds with the potential to interact with the target enzyme. This initial screening step drastically reduced the number of candidates, saving substantial time and resources [5].

The selected compounds then underwent further virtual simulations, where AI and ML algorithms accurately predicted their interactions with the enzyme's active site. This allowed researchers to prioritize the most promising candidates for experimental validation, leading to a more targeted and efficient approach to drug development [4, 10].

**3. Advantages of AI and ML in Drug Research**

Advancements in technology have revolutionized various industries, and the field of medicine is no exception. One of the most significant developments in recent years is the application of Artificial Intelligence (AI) and Machine Learning (ML) in drug research. AI and ML have proven to be powerful tools in this domain, providing numerous advantages that were previously unimaginable. In this essay, we will explore the advantages of AI and ML in drug research, focusing on increased efficiency in drug discovery, enhanced accuracy in predicting drug efficacy and toxicity, and the facilitation of personalized medicine [1, 8].

One of the primary advantages of AI and ML in drug research is the increased efficiency in the drug discovery process. Traditionally, drug discovery has been a time-consuming and costly endeavor. However, with the advent of AI and ML, researchers can leverage vast datasets of known drug molecules and train ML algorithms to identify patterns and make predictions. This AI-based drug discovery process enables researchers to streamline their efforts and create more efficient medicines for patients. Additionally, the automation provided by AI and ML technologies reduces the need for manual labor, freeing up researchers to focus on more complex tasks [9]. Combination drug delivery, for example, can be made more efficient by using AI algorithms to optimize drug combinations based on efficacy and safety data [9]. Furthermore, AI is currently taking over repetitive jobs in the pharmaceutical industry, allowing researchers to tackle more challenging problems and make breakthroughs that were previously unattainable [9]. Overall, the integration of AI and ML in drug research has the potential to significantly increase the efficiency of the drug discovery process, leading to the development of novel and more effective medications.

Another advantage of AI and ML in drug research is the enhanced accuracy in predicting drug efficacy and toxicity. ML algorithms can be trained to learn from vast amounts of data and make accurate predictions about various aspects of drug development, such as drug release, monitoring, dosage optimization, and toxicity [3]. By using supervised learning techniques, ML models can learn from labeled datasets and make predictions based on new, unseen data [3]. This ability to predict drug efficacy and toxicity with high accuracy is crucial in the early stages of drug development, as it helps researchers identify promising candidates and avoid

potential failures [7]. Additionally, the use of AI and ML in drug research has led to the development of prediction systems that can significantly reduce the time and cost associated with clinical trials [7]. These systems analyze vast amounts of data to predict the safety and effectiveness of drug candidates, allowing researchers to make informed decisions and prioritize resources [6]. Furthermore, AI offers the ability to design drug molecules from scratch, leveraging ML algorithms to generate novel compounds with desired properties [6]. This capability opens up new possibilities for drug development, enabling researchers to explore uncharted territories and potentially discover breakthrough medications.

One of the most promising applications of AI and ML in drug research is the facilitation of personalized medicine. Personalized medicine aims to provide tailored treatments based on individual patient characteristics, such as genetics, lifestyle, and medical history. AI and ML have the ability to analyze comprehensive patient information and generate personalized treatment plans [1].

The successful discovery of Abaucin highlights several advantages of utilizing AI and ML in drug research:

a. Speed and Efficiency: AI-driven drug discovery significantly reduces the time needed to identify potential drug candidates, accelerating the overall drug development process.

b. Cost-Effectiveness: By narrowing down the pool of candidates, AI and ML save considerable costs associated with synthesizing and testing numerous compounds.

c. Enhanced Targeting: AI technologies help researchers identify drugs with greater specificity, minimizing adverse effects and increasing therapeutic efficacy.

d. Personalized Medicine: AI-driven drug discovery enables a deeper understanding of patient-specific factors, fostering the development of personalized medicines tailored to individual needs.

**4. What challenges come with the use of AI and machine learning in drug research?**

Despite the potential benefits of using AI and machine learning in drug research, there are still challenges that need to be addressed. Firstly, the process of training the machine learning model was time-consuming, taking an hour and a half in the current study. Additionally, further laboratory testing is required to confirm the potential effectiveness of any identified compounds. Furthermore, pathogens have the ability to evolve and adjust to different strategies used against them, making it difficult to identify compounds that have broad-spectrum activity [8]. As such, broad-spectrum antibiotics are considered suboptimal in drug research. Moreover, AI can help identify new structures and compounds that have not been previously encountered. In the current study, a message-passing deep neural network was used to analyze 6,680 compounds from the Drug Repurposing Hub at the Broad Institute. AI can be used to analyze a large number of compounds, and help identify new structures and compounds that can potentially be used as antibiotics. The model identified a compound, abaucin, that was effective against *Acinetobacter baumannii.* Furthermore, the use of AI and machine learning can also help with drug repurposing efforts. AI and machine learning present an important avenue of exploration for new antibiotic drugs, which can potentially increase the rate at which new classes of antibiotics are discovered. In an ideal scenario, AI can also decrease the cost associated with the discovery of new antibiotics. However, it is estimated that the first AI antibiotics may not be available commercially until 2030 [3].

By analyzing vast amounts of data, these technologies have the potential to identify potential drug candidates efficiently. The study conducted by a team of

researchers from MIT and McMaster University exemplifies the success of this approach, as it utilized AI screening methods to identify a novel antibiotic called abaucin [5] with a unique chemical structure. This breakthrough demonstrates the potential of AI and ML in accelerating the drug discovery process. However, it is important to note that despite these advancements, the availability of AI antibiotics is not expected until 2030, emphasizing the need for continued research and development in this area [1, 3, 5, 8]. Additionally, the use of AI and machine learning in drug repurposing efforts is also highlighted, suggesting that these technologies can be beneficial in finding new applications for existing drugs. Moreover, the ability of AI to identify new antibiotics to combat drug-resistant pathogens is a significant contribution to the field of antimicrobial resistance. Overall, this research paper underscores the transformative potential of AI and machine learning in revolutionizing new drug research, while also acknowledging the limitations and the need for further investigation and future research directions [3, 5, 6, 7, 9].

**Conclusion**

The success story of Abaucin exemplifies the transformative potential of AI and ML in drug discovery. These technologies have revolutionized the way researchers identify potential drug candidates, streamlining the process and reducing costs. As AI and ML continue to evolve, the pharmaceutical industry can expect further breakthroughs, bringing new hope to patients worldwide and pushing the boundaries of medical science.

## References:

[1] Ahmed, Z., Mohamed, K., Zeeshan, S., & Dong, X. (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database, 2020. https://doi.org/10.1093/database/baaa010

[2] Gallagher, B. J. (2023). New superbug-killing antibiotic discovered using AI. BBC News. https://www.bbc.com/news/health-65709834

[3] Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity, 25(3), 1315–1360. https://doi.org/10.1007/s11030-021-10217-3

[4] Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opinion on Drug Discovery, 16(9), 949–959. https://doi.org/10.1080/17460441.2021.1909567

[5] Liu, G., Catacutan, D. B., Rathod, K., Swanson, K., Jin, W., Mohammed, J. C., Chiappino-Pepe, A., Syed, S. A., Fragis, M., Rachwalski, K., Magolan, J., Surette, M. G., Coombes, B. K., Jaakkola, T., Barzilay, R., Collins, J. J., & Stokes, J. M. (2023). Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nature Chemical Biology. https://doi.org/10.1038/s41589-023-01349-8

[6] Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 24(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014

[7] Muster, W., Breidenbach, A., Fischer, H., Kirchner, S., Müller, L., & Pähler, A. (2008). Computational toxicology in drug development. Drug Discovery Today, 13(7-8), 303–310. https://doi.org/10.1016/j.drudis.2007.12.007

[8] Nguyen, M.-T., Nguyen, T., & Tran, T. (2022). Learning to discover medicines. International Journal of Data Science and Analytics. https://doi.org/10.1007/s41060-022-00371-8

[9] Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2020). Artificial intelligence in drug discovery and development. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2020.10.010

[10] Vemula, D., Jayasurya, P., Sushmitha, V., Kumar, Y. N., & Bhandari, V. (2022). CADD, AI and ML in Drug Discovery: A Comprehensive Review. European Journal of Pharmaceutical Sciences, 106324. https://doi.org/10.1016/j.ejps.2022.106324